Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 15/20 | 1.00 |
| ▸ | EGFR | P00533 | 6/20 | 0.76 |
| ▸ | KDR | P35968 | 10/20 | 0.74 |
| ▸ | CSK | P41240 | 1/20 | 0.73 |
| ▸ | TEK | Q02763 | 1/20 | 0.73 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.72 |
| ▸ | LCK | P06239 | 2/20 | 0.72 |
| ▸ | RET | P07949 | 2/20 | 0.72 |
| ▸ | MET | P08581 | 2/20 | 0.72 |
| ▸ | MAPT | P10636 | 2/20 | 0.72 |
| ▸ | LTK | P29376 | 2/20 | 0.72 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.72 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.72 |
| ▸ | CIT | O14578 | 1/20 | 0.72 |
| ▸ | GAK | O14976 | 1/20 | 0.72 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.72 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.72 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.72 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.72 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19154598 | 0.87 | SRC (0.80) | SRCEGFRKDREPHB4LCK | |
| SCHEMBL3531151 | 0.87 | SRC (0.86) | SRCEGFRKDREPHB4LCK | |
| SCHEMBL30416288 | 0.86 | EGFR (0.86) | SRCEGFRKDREPHB4LCK | |
| SCHEMBL22383954 | 0.86 | EGFR (0.86) | SRCEGFRKDREPHB4LCK | |
| SCHEMBL11304 | 0.86 | EGFR (0.86) | SRCEGFRKDREPHB4LCK | |
| SCHEMBL28424819 | 0.86 | SRC (0.85) | SRCEGFRKDREPHB4LCK | |
| SCHEMBL13529060 | 0.86 | SRC (0.84) | SRCEGFRKDREPHB4LCK | |
| SCHEMBL15591842 | 0.85 | EGFR (0.89) | SRCEGFRKDREPHB4LCK | |
| SCHEMBL3206775 | 0.85 | SRC (1.00) | SRCEGFRKDRCSKTEK | |
| SCHEMBL799681 | 0.85 | EGFR (0.83) | SRCEGFRKDREPHB4LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492560-B2 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2013-07-23 | — | — | US | disclosed |
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | STOKES ELAINE S E (GB) | 2012-08-02 | — | — | US | disclosed |
| EP-2050744-A1 | Quinazoline derivatives as angiogenesis inhibitors | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| US-7074800-B1 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2006-07-11 | — | — | US | disclosed |
| US-20060004017-A1 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB | 2006-01-05 | — | — | US | disclosed |
| EP-1553097-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AND INTERMEDIATES THEREFORE | AstraZeneca AB (SE) | 2005-07-13 | — | — | EP | disclosed |
| EP-1154774-B1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2005-06-22 | — | — | EP | disclosed |
| EP-1154774-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AstraZeneca AB (SE) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000047212-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | VEGFA, FLT1, KDR | SRC 1517/4885EGFR 500/4885KDR 3/4885 |
| US-20060004017-A1 | Quinazoline derivatives as angiogenesis inhibitors | FLT4, NOS3, FLT1 | SRC 1276/4885EGFR 549/4885KDR 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.